Peritoneal dialysis solutions

Peritoneal Dialysis International

Volumn 21, Issue SUPPL. 3, 2001, Pages

  Wang, Tao ^a   Lindholm, Bengt ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Fluid balance; Peritoneal dialysis solution; Peritoneal membrane

Indexed keywords

AMINO ACID; ANTIHYPERTENSIVE AGENT; BICARBONATE; CALCIUM; GLUCOSE; GLUCOSE POLYMER; HYALURONIC ACID; ICODEXTRIN; LACTIC ACID; OSMOTIC AGENT; PERITONEAL DIALYSIS FLUID;

ARTICLE; BIOCOMPATIBILITY; CONTROLLED STUDY; DIALYSIS MEMBRANE; FLUID BALANCE; HUMAN; LONG TERM CARE; MEDICAL RESEARCH; NONHUMAN; OUTCOMES RESEARCH; PERITONEAL DIALYSIS; PERITONEAL FLUID; PERITONEUM; PRIORITY JOURNAL;

EID: 0035571675     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080102103s15     Document Type: Article

References (72)

1. Peritoneal dialysis: Better than, equal to, or worse than hemodialysis? Data worth knowing before choosing a dialysis modality
2. Hemodialysis versus peritoneal dialysis: A comparison of adjusted mortality rates
3. CAPD viability: A long-term comparison with hemodialysis
4. Longitudinal changes in peritoneal kinetics: The effects of peritoneal dialysis and peritonitis
5. Biocompatibility of peritoneal dialysis solutions
6. Membrane longevity in peritoneal dialysis: Impact of infection and bio-incompatible solutions
7. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration
8. Biological significance of reducing glucose degradation products in peritoneal dialysis fluids
9. Glucose degradation products and the peritoneal mesothelium
10. Strategies to reduce glucose exposure in peritoneal dialysis patients
11. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products
12. A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution-clinical benefits
13. In vitro effects of bicarbonate and bicarbonate-lactate buffered peritoneal dialysis solutions on mesothelial and neutrophil function
14. Pre-clinical biocompatibility testing of peritoneal dialysis solutions
15. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels
16. Introduction
17. Amino acid solutions for CAPD-rationale and clinical experience
18. Treatment of malnutrition with 1.1% amino acid peritoneal dialysis solution: Results of a multicenter outpatient study
19. Biocompatibility of a peritoneal dialysis solution with amino acids: Histological evaluation in the rabbit
20. Biocompatibility of new peritoneal dialysis solutions: Clinical experience
21. Glucose and glycerol compared as osmotic agents for peritoneal dialysis
22. Extended use of a glycerol dialysate in the treatment of diabetic CAPD patients
23. Anti-hypertensive effect of low Na concentration (120 mEq/L) solution for CAPD patients
24. Improved solutions for peritoneal dialysis: Physiological calcium solutions, osmotic agents and buffers
25. History, chemical, and pharmaceutical development of icodextrin
26. Kinetics of icodextrin
27. Decreased in vitro formation of AGEs with Extraneal solution compared to dextrose-containing peritoneal dialysis solutions
28. Effect of icodextrin peritoneal dialysis solution on cell proliferation in vitro
29. Icodextrin effluent leads to a greater proliferation than glucose effluent of human mesothelial cells studied ex vivo
30. Advanced glycosylation end-products in diabetic rats on peritoneal dialysis using various solutions
31. Effects of icodextrin in automated peritoneal dialysis on blood pressure and bioelectrical impedance analysis
32. Peritoneal kinetics and mesothelial markers in CCPD using icodextrin for daytime dwell for two years
33. Comparison of icodextrin and glucose solutions for the daytime dwell in automated peritoneal dialysis
34. The use of glucose polymer (icodextrin) in peritoneal dialysis: An overview
35. A United Kingdom multicenter study of icodextrin in continuous ambulatory peritoneal dialysis
36. Peritonitis occurrence in a multicenter study of icodextrin and glucose in CAPD
37. Icodextrin 7.5% dialysate solution (glucose polymer) in patients with ultrafiltration failure: Extension of CAPD technique survival
38. Icodextrin with nitroprusside increases ultrafiltration and peritoneal transport during long CAPD dwells
39. Recommended clinical practices for maximizing peritoneal dialysis clearances
40. Adequacy, nutrition and outcome in peritoneal dialysis: Is there a link?
41. Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients
42. Increased peritoneal permeability is associated with decreased fluid and small-solute removal and higher mortality in CAPD patients
43. Peritoneal solute transport predicts survival on CAPD independently of residual renal function
44. How to maintain fluid balance in long-term peritoneal dialysis
45. Have we underestimated the importance of fluid balance for survival of PD patients?
46. Time dependence of solute removal during a single exchange
47. Biocompatibility of new peritoneal dialysis solutions: What can we hope to achieve?
48. Endotoxin and immune activation in chronic heart failure: A prospective cohort study
49. Peritoneal transport physiology: Insights from basic research
50. Net ultrafiltration in peritoneal dialysis: Role of direct fluid absorption into peritoneal tissue
51. Hyaluronan decreases peritoneal fluid absorption in peritoneal dialysis
52. Hyaluronan prevents the decrease in net fluid removal caused by increased dialysate fill volume
53. Hyaluronan decreases peritoneal fluid absorption: Effect of molecular weight and concentration of hyaluronan
54. Intraperitoneal hyaluronan administration in conscious rats: Absorption, metabolism, and effects on peritoneal fluid dynamics
55. Dialysis solution containing hyaluronan: Effect on peritoneal permeability and inflammation in rats
56. Hyaluronan and peritoneal ultrafiltration: A test of the "filter-cake" hypothesis
57. Localization of hyaluronan in various muscular tissues. A morphological study in the rat
58. The source and possible significance of hyaluronan in the peritoneal cavity
59. Physiological function of connective tissue polysaccharides
60. Function of hyaluronan
61. Hyaluronan
62. Oxygen radicals, enzymes, and fluid transport through pericardial interstitium
63. Effects of electric charge on hydraulic conductivity of pulmonary interstitium
64. Hyaluronan decreases peritoneal fluid absorption: Effect of molecular weight and concentration of hyaluronan
65. Ultrastructural identification of a novel membrane structure on peritoneal surface
66. Influence of phosphatidylcholine on lymphatic absorption during peritoneal dialysis in the rat
67. Improvement of impaired ultrafiltration after addition of phosphatidylcholine in patients on CAPD
68. Phosphatidylcholine and chondroitin sulfate in peritoneal dialysis fluids to preserve membrane function
69. Lubrication of the peritoneum
70. Nature and disposition of intracavity and intramembranous phospholipid surface-active material and its role in peritoneal dialysis
71. Role of surfactant in peritoneal dialysis
72. Hyaluronan preserves peritoneal membrane transport properties